TELA Bio (TELA) Cash & Equivalents Growth (1y) (2019 - 2026)

TELA Bio (TELA) Cash & Equivalents Growth (1y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 4.15%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 24.05%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn -12.13%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 100.41%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -22.13%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 23.57%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -7.71%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -10.02%
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 141.82%
10 TELA Bio 38.36 Mn -1.18 Mn 12.52 Mn -7.69%

Historic Data

Download Data
DateValue
Mar 31, 2026 -7.69%
Dec 31, 2025 -3.46%
Sep 30, 2025 71.74%
Jun 30, 2025 32.01%
Mar 31, 2025 15.32%
Dec 31, 2024 12.71%
Sep 30, 2024 -70.27%
Jun 30, 2024 -59.40%
Mar 31, 2024 23.30%
Dec 31, 2023 11.21%
Sep 30, 2023 7.33%
Jun 30, 2023 135.40%
Mar 31, 2023 -8.76%
Dec 31, 2022 -4.35%
Sep 30, 2022 1.10%
Jun 30, 2022 -54.02%
Mar 31, 2022 -49.85%
Dec 31, 2021 -40.95%
Sep 30, 2021 -34.16%
Jun 30, 2021 -29.46%